CROs/Service Providers

WuXi AppTec acquires HD Biosciences

Friday, January 20, 2017

WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired HD Biosciences (HDB), a biology-focused preclinical drug discovery CRO. After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.

[Read More]

CROS NT expands operations in India

Wednesday, January 18, 2017

CROS NT, a patient-centric and data-driven CRO, has announced the opening of its new office in Bangalore, India. The Bangalore office is the fourth global office established by CROS NT in the last six years, including branches in Italy, Germany, the U.K. and the U.S.

[Read More]

Parexel to restructure

Friday, January 13, 2017

Chairman, CEO and the Corporate Vice President and Interim CFO of Parexel International has approved a plan to restructure its operations to improve the productivity and efficiency of the company, simplify the organization and streamline decision-making, thereby enhancing client engagement. The restructuring initiative is company-wide.

[Read More]

LabCorp to acquire assets of Mount Sinai Clinical Outreach Laboratories

Wednesday, January 11, 2017

Laboratory Corporation of America Holdings (LabCorp), a life sciences company, and the Mount Sinai Health System, one of the largest health systems in metropolitan New York City, have entered into a definitive agreement for LabCorp to acquire assets of Mount Sinai’s Clinical Outreach Laboratories. When the transaction is complete, LabCorp will be available to provide comprehensive laboratory services to physicians and patients that currently use Mount Sinai’s outreach laboratory.

[Read More]

Helomics completes restructuring into fully-integrated CRO

Thursday, December 22, 2016

Helomics, a privately held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic and biotech industries, has announced the completion of the final phase of its corporate realignment toward becoming a fully-integrated clinical contract research and clinical products organization (ICCRO).  

[Read More]

Study: CRO turnover remains high

Thursday, December 22, 2016

Turnover in the U.S. for clinical monitoring jobs (the function that monitors participants’ health during a clinical trial) at CROs remained high at 25.1% in 2015, almost the same as the previous year’s reported 25.4% (2014). Turnover remained high despite the 7% spike in average salaries for professional positions from 2014 to 2015, according to the 18th annual CRO Industry Global Compensation and Turnover Survey, conducted by HR+Survey Solutions, a specialty compensation consulting and research firm.

[Read More]

Charles River Laboratories launches CRISPR/Cas9 genome engineering technology

Thursday, December 8, 2016

Charles River Laboratories International has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute of MIT and Harvard, Charles River can now offer custom in vivo and in vitrogenome editing. With this technology, Charles River will be able to develop more translational research models that will ultimately improve the efficiency and effectiveness of the drug discovery process.

[Read More]

Center Point Clinical Services launches site-less CRO

Thursday, December 8, 2016

Center Point Clinical Services, creator of the Clinical Trial Research Pharmacist (CTRP) solution, has launched the world’s first site-less technology CRO. The site-less CRO model is designed to support the evolving world of clinical trials by empowering study sponsors to de-risk the clinical trial process, increase quality, reduce costs and ensure robust data for regulatory submissions.

[Read More]

Almac Group, inVentiv Health partner

Thursday, December 8, 2016

Almac Clinical Technologies, part of the Almac Group, a privately held contract pharmaceutical development and manufacturing organization, has announced the formation of a strategic partnership with inVentiv Health, a biopharma outsourcing company combining a leading CRO and the industry’s only contract commercial organization (CCO). The partnership presents an opportunity for both organizations to provide clients and sites with streamlined access to best-in-class clinical trial Interactive Response Technology (IRT) solutions.

[Read More]